Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (6230)	11/6/1998 6:19:00 PM
From: BigKNY3	Read Replies (1) \| Respond to of 9523

Pfizer -4: Expanded Indications For Existing Products >PFE 11/06/98 Dow Jones News Service As it continues to expand indications for existing products, Pfizer said clinical programs are underway for Zithromax, Lipitor, Norvasc, Zyrtec, Trovan and Viagra. New indications for Trovan, an antibiotic launched in February, are underway for pediatric use. The antihypertensive Norvasc is being studied for congestive heart failure. Zithromax, another antibiotic, is being explored for atherosclerosis, a general term for diseases that can affect the arteries of vital organs. In one Zithromax study, called the WIZARD trial, Pfizer is evaluating the effects of chlamydia on coronary disease. The company has enrolled 3,500 heart attack patients with chlamydia infection in the trial and administers Zithromax once-weekly. In a five-year study of the cholesterol-lowering drug Lipitor, Pfizer is attempting to demonstrate increased benefit of achieving lower cholesterol levels. The company has enrolled 8,600 patients in the 250-site study.